Cadence Capital
Level 11, 131 Macquarie Street, Sydney, New South Wales, 2000, Australia
Overview
Cadence Capital is a fundamental and technical analysis investment they fund administration necessitates a great deal of information synthesis and reading. They have all financial books over the years and refer to them from time to time. They team has put together a collection of books that have affected they investing style or provided insight into the investment process.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Asset Management
- Consulting
- Financial Services
- Venture Capital
Investment portfolio
- Reprieve Cardiovascular
Participated · Series B · Aug 2025
Reprieve Cardiovascular is a clinical-stage medical device company headquartered in Milford, Massachusetts, developing the Reprieve system to personalize decongestion management for patients with acute decompensated heart failure (ADHF). The Reprieve system combines real-time physiological monitoring with automated recommendations and precise diuretic dosing while replenishing saline to support kidney function, aiming to safely, quickly, and thoroughly remove excess fluid. The company completed a randomized FASTR pilot study that met primary efficacy and safety endpoints and has initiated the larger FASTR II pivotal trial, enrolling its first patient. FASTR II plans to enroll up to 400 patients across the United States and Europe and will support a future premarket approval submission in the United States. Proceeds from the oversubscribed $61 million Series B, which combined equity investment with a debt facility, will support rapid execution of the FASTR II trial and key commercial readiness activities. Reprieve says it seeks to improve outcomes and reduce readmissions for the more than 25 million people globally who suffer from heart failure. Reprieve Cardiovascular is a development-stage, privately held medical device company developing the Reprieve System, an intelligent automated diuretic and fluid-management platform to personalize decongestion for acute decompensated heart failure patients. The system monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement, aiming to safely and quickly remove excess fluid, improve outcomes, and reduce readmissions. The company emerged from stealth after announcing a $42 million Series A to advance clinical and development programs. Proceeds will support the ongoing FASTR pilot trial (initiated in 2022) and an upcoming pivotal trial; the FASTR trial is enrolling patients in the United States and Europe. Leadership has grown with domain experts across product development, regulatory, clinical, and commercial strategy. Reprieve is headquartered in Milford, Massachusetts.
Team
No current team members are available.